The Technical Analyst
23andMe Holding Co. [ME]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
23andMe Holding Co. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-4.69% $0.482
America/New_York / 19 apr 2024 @ 15:03
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 232.77 mill |
| EPS: | -1.110 |
| P/E: | -0.430 |
| Earnings Date: | May 25, 2024 |
| SharesOutstanding: | 482.92 mill |
| Avg Daily Volume: | 7.44 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.430 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.430 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.433 - 0.543 ( +/- 11.27%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-04 | Hibbs Kathy L | Buy | 38 548 | Class A Common Stock |
| 2024-04-04 | Hibbs Kathy L | Sell | 38 548 | Class A Common Stock |
| 2024-04-04 | Hibbs Kathy L | Sell | 38 548 | Stock Option (Right to Buy) |
| 2024-03-21 | Hibbs Kathy L | Buy | 38 548 | Class A Common Stock |
| 2024-03-21 | Hibbs Kathy L | Sell | 38 548 | Class A Common Stock |
| INSIDER POWER |
|---|
| 74.39 |
| Last 100 transactions |
| Buy: 15 289 110 | Sell: 2 056 788 |
Forecast:
16:00 - $0.483
Live Trading Signals (every 1 min)
Forecast
1: 15:12 - $0.485
Forecast 2: 16:00 - $0.483
Forecast 3: 16:00 - $0.483
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.482 (-4.69% ) |
| Volume | 14.73 mill |
| Avg. Vol. | 7.44 mill |
| % of Avg. Vol | 197.92 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ME
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $0.596 | N/A | Active |
|---|
ME
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-04-18 08:00:00 - Press Release
23andme Announces Ceo's Intention To Pursue A Potential Take-private
South san francisco, calif., april 18, 2024 (globe newswire) -- 23andme holding co. (nasdaq: me), a leading human genetics and biopharmaceutical company, has been made aware that anne wojcicki, chief executive officer, co-founder, and chair of the board of directors of 23andme, is considering making a proposal to acquire all of the outstanding shares of 23andme that she does not currently own, as she stated in an amendment dated april 17, 2024 to her schedule 13d filing with the securities and exchange commission. ms. wojcicki currently owns shares constituting more than 20% of the total outstanding shares and entitling her to approximately 49% of the voting power of the total outstanding shares of 23andme...
2024-04-05 16:05:00 - Press Release
23andme To Present Data On Two Clinical Stage Immuno-oncology Programs At The American Association For Cancer Research (aacr) Annual Meeting 2024
San diego, april 05, 2024 (globe newswire) -- 23andme holding co. (nasdaq: me) (“23andme”), a leading human genetics and biopharmaceutical company, will present data on its two clinical stage programs, 23me-01473 targeting ulbp6, and 23me-00610 targeting cd200r1, at the american association for cancer research (aacr) annual meeting 2024, taking place in san diego, ca, april 5-10, 2024.
2024-03-20 07:30:00 - Press Release
23andme Initiates Phase 1 Clinical Trial For Its Dual Mechanism Antibody, 23me-01473, Targeting Ulbp6
South san francisco, calif., march 20, 2024 (globe newswire) -- 23andme holding co. (nasdaq: me), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a phase 1 clinical trial evaluating 23me-01473 (‘1473) in advanced solid tumors. the target for the new investigational antibody, ulbp6, was discovered through 23andme's proprietary research platform, the world's largest recontactable database of de-identified human genetic and phenotypic information. this is the third drug target genetically validated by the 23andme research platform to enter the clinic in under 4 years.
2024-03-19 08:00:00 - Press Release
23andme Launches New Feature Connecting Customers To Historical Individuals From Hundreds And Even Thousands Of Years Ago
Built upon peer-reviewed published science, the historical matches feature weaves customers' ancestral connections into the story of human history and migration built upon peer-reviewed published science, the historical matches feature weaves customers' ancestral connections into the story of human history and migration
2024-03-06 07:30:00 - Press Release
23andme Launches New Genetic Reports On Common Forms Of Cancer
23andme customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (prs) developed by 23andme 23andme customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (prs) developed by 23andme
Latest News
2024-04-18 19:00:51 - Fast Company
23andMe wants to go private. It's the latest in a line of failed SPACs
Like a number of companies that went public during the pandemic, 23andMe has for months been trying to manage a terrible case of SPAC-itis, an inflammation that causes plunging stock values due to the business being, as one analyst put it, not “ready for prime time.”
2024-04-18 11:51:54 - Proactive Investors
23andMe CEO reveals take-private plan
23andMe Holding Co.'s shares surged after CEO Anne Wojcicki revealed plans to potentially take the struggling DNA testing firm private. The announcement follows the company's dismal performance since going public three years ago, with shares plummeting by over 90% amid sluggish adoption of its personalized DNA services.
2024-04-18 10:30:39 - Investopedia
23andMe CEO Wojcicki Plans To Take DNA-Testing Firm Private
23andMe (ME) chief executive Anne Wojcicki is seeking to take the DNA-testing company private less than three years after it went public, the firm said in a Securities and Exchange Commission (SEC) filing.
2024-04-18 10:07:01 - CNBC
23andMe CEO Anne Wojcicki considers taking company private
23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private
2024-04-18 06:35:21 - 24/7 Wall Street
23andMe May Disappear as Public Stock
Battered 23andMe Holding Co. (NASDAQ: ME), its shares driven down to penny stock levels, may disappear from the public markets completely.
2024-04-17 23:13:00 - Reuters
23andMe CEO Wojcicki considering taking firm private, filing shows
23andMe co-founder and chief executive Anne Wojcicki is considering making an offer to buy the genetics testing company in a potential go-private transaction, a regulatory filing on late Wednesday showed.
2024-04-05 16:05:00 - GlobeNewsWire
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, will present data on its two clinical stage programs, 23ME-01473 targeting ULBP6, and 23ME-00610 targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego, CA, April 5-10, 2024.
2024-03-24 03:23:00 - The Motley Fool
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
Shares of 23andMe have been hurt severely since the company's stock market debut in 2021. Several billionaire investors acquired shares of 23andMe during the last three months of 2023.
2024-02-17 12:00:21 - The Guardian
‘There are no serious safeguards': can 23andMe be trusted with our DNA?
The at-home genetic testing company is dealing with financial woes and a security breach. What does that mean for customers?
2024-02-08 12:25:38 - CNBC
23andMe considers splitting up company to revive stock price
23andMe reported dismal third-quarter fiscal 2024 results and discussed splitting itself in two to help juice its stock price.